Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lenora M. Noroski is active.

Publication


Featured researches published by Lenora M. Noroski.


Nature Genetics | 2009

Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness

Chantal Lagresle-Peyrou; Emmanuelle Six; Capucine Picard; Frédéric Rieux-Laucat; Vincent Michel; Andrea Ditadi; Corinne Demerens-de Chappedelaine; Estelle Morillon; Françoise Valensi; Karen L. Simon-Stoos; James C. Mullikin; Lenora M. Noroski; Céline Besse; N Wulffraat; Alina Ferster; Manuel M Abecasis; Fabien Calvo; Christine Petit; Fabio Candotti; Laurent Abel; Alain Fischer; Marina Cavazzana-Calvo

Reticular dysgenesis is an autosomal recessive form of human severe combined immunodeficiency characterized by an early differentiation arrest in the myeloid lineage and impaired lymphoid maturation. In addition, affected newborns have bilateral sensorineural deafness. Here we identify biallelic mutations in AK2 (adenylate kinase 2) in seven individuals affected with reticular dysgenesis. These mutations result in absent or strongly decreased protein expression. We then demonstrate that restoration of AK2 expression in the bone marrow cells of individuals with reticular dysgenesis overcomes the neutrophil differentiation arrest, underlining its specific requirement in the development of a restricted set of hematopoietic lineages. Last, we establish that AK2 is specifically expressed in the stria vascularis region of the inner ear, which provides an explanation of the sensorineural deafness in these individuals. These results identify a previously unknown mechanism involved in regulation of hematopoietic cell differentiation and in one of the most severe human immunodeficiency syndromes.


The New England Journal of Medicine | 2010

Vaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency

Niraj C. Patel; Paula M. Hertel; Mary K. Estes; Maite de la Morena; Ann Petru; Lenora M. Noroski; Paula A. Revell; I. Celine Hanson; Mary E. Paul; Howard M. Rosenblatt; Stuart L. Abramson

Live pentavalent human-bovine reassortant rotavirus vaccine is recommended in the United States for routine immunization of infants. We describe three infants, two with failure to thrive, who had dehydration and diarrhea within 1 month after their first or second rotavirus immunization and subsequently received a diagnosis of severe combined immunodeficiency. Rotavirus was detected, by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay, in stool specimens obtained from all three infants, and gene-sequence analysis revealed the presence of vaccine rotavirus. These infections raise concerns regarding the safety of rotavirus vaccine in severely immunocompromised patients.


The Journal of Allergy and Clinical Immunology | 2017

Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders

Asbjørg Stray-Pedersen; Hanne Sørmo Sorte; Pubudu Saneth Samarakoon; Tomasz Gambin; Ivan K. Chinn; Zeynep Coban Akdemir; Hans Christian Erichsen; Lisa R. Forbes; Shen Gu; Bo Yuan; Shalini N. Jhangiani; Donna M. Muzny; Olaug K. Rødningen; Ying Sheng; Sarah K. Nicholas; Lenora M. Noroski; Filiz O. Seeborg; Carla M. Davis; Debra L. Canter; Emily M. Mace; Timothy J. Vece; Carl E. Allen; Harshal Abhyankar; Philip M. Boone; Christine R. Beck; Wojciech Wiszniewski; Børre Fevang; Pål Aukrust; Geir E. Tjønnfjord; Tobias Gedde-Dahl

Background: Primary immunodeficiency diseases (PIDDs) are clinically and genetically heterogeneous disorders thus far associated with mutations in more than 300 genes. The clinical phenotypes derived from distinct genotypes can overlap. Genetic etiology can be a prognostic indicator of disease severity and can influence treatment decisions. Objective: We sought to investigate the ability of whole‐exome screening methods to detect disease‐causing variants in patients with PIDDs. Methods: Patients with PIDDs from 278 families from 22 countries were investigated by using whole‐exome sequencing. Computational copy number variant (CNV) prediction pipelines and an exome‐tiling chromosomal microarray were also applied to identify intragenic CNVs. Analytic approaches initially focused on 475 known or candidate PIDD genes but were nonexclusive and further tailored based on clinical data, family history, and immunophenotyping. Results: A likely molecular diagnosis was achieved in 110 (40%) unrelated probands. Clinical diagnosis was revised in about half (60/110) and management was directly altered in nearly a quarter (26/110) of families based on molecular findings. Twelve PIDD‐causing CNVs were detected, including 7 smaller than 30 Kb that would not have been detected with conventional diagnostic CNV arrays. Conclusion: This high‐throughput genomic approach enabled detection of disease‐related variants in unexpected genes; permitted detection of low‐grade constitutional, somatic, and revertant mosaicism; and provided evidence of a mutational burden in mixed PIDD immunophenotypes.


The Journal of Allergy and Clinical Immunology | 2009

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning

Niraj C. Patel; Javier Chinen; Howard M. Rosenblatt; I. Celine Hanson; Robert A. Krance; Mary E. Paul; Stuart L. Abramson; Lenora M. Noroski; Carla M. Davis; Filiz O. Seeborg; S.B. Foster; Kathryn Leung; Betty S. Brown; Jerome Ritz; William T. Shearer

BACKGROUND The effect of pretransplantation conditioning on the long-term outcomes of patients receiving hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) has not been completely determined. OBJECTIVE We sought to assess the outcomes of 23 mostly conditioned patients with SCID and compare their outcomes with those of 25 previously reported nonconditioned patients with SCID who underwent transplantation. METHODS In the present study we reviewed the medical records of these 23 consecutive, mostly conditioned patients with SCID who underwent transplantation between 1998 and 2007. RESULTS Eighteen patients (median age at transplantation, 10 months; range, 0.8-108 months) received haploidentical mismatched related donor, matched unrelated donor, or mismatched unrelated donor transplants, 17 of whom received pretransplantation conditioning (with 1 not conditioned); 13 (72%) patients engrafted with donor cells and survive at a median of 3.8 years (range, 1.8-9.8 year); 5 (38%) of 13 patients require intravenous immunoglobulin; and 6 of 6 age-eligible children attend school. Of 5 recipients (median age at transplantation, 7 months; range, 2-23 months) of matched related donor transplants, all 5 engrafted and survive at a median of 7.5 years (range, 1.5-9.5 year), 1 recipient requires intravenous immunoglobulin, and 3 of 3 age-eligible children attend school. Gene mutations were known in 16 cases: mutation in the common gamma chain of the IL-2 receptor (IL2RG) in 7 patients, mutation in the alpha chain of the IL-7 receptor (IL7RA) in 4 patients, mutation in the recombinase-activating gene (RAG1) in 2 patients, adenosine deaminase deficiency (ADA) in 2 patients, and adenylate kinase 2 (AK2) in 1 patient. Early outcomes and quality of life of the previous nonconditioned versus the present conditioned cohorts were not statistically different, but longer-term follow-up is necessary for confirmation. CONCLUSIONS Hematopoietic stem cell transplantation in patients with SCID results in engraftment, long-term survival, and a good quality of life for the majority of patients with or without pretransplantation conditioning.


Clinical and Experimental Immunology | 2014

Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray

D. K. Bayer; Caridad Martinez; Hanne Sørmo Sorte; Lisa R. Forbes; G. J. Demmler-Harrison; I. C. Hanson; N. M. Pearson; Lenora M. Noroski; S. R. Zaki; W. J. Bellini; Magalie S. Leduc; Yaping Yang; Christine M. Eng; Ankita Patel; Olaug K. Rødningen; Donna M. Muzny; Richard A. Gibbs; Ian M. Campbell; Chad A. Shaw; M. W. Baker; Victor Wei Zhang; James R. Lupski; Jordan S. Orange; Filiz O. Seeborg; Asbjørg Stray-Pedersen

In areas without newborn screening for severe combined immunodeficiency (SCID), disease‐defining infections may lead to diagnosis, and in some cases, may not be identified prior to the first year of life. We describe a female infant who presented with disseminated vaccine‐acquired varicella (VZV) and vaccine‐acquired rubella infections at 13 months of age. Immunological evaluations demonstrated neutropenia, isolated CD4 lymphocytopenia, the presence of CD8+ T cells, poor lymphocyte proliferation, hypergammaglobulinaemia and poor specific antibody production to VZV infection and routine immunizations. A combination of whole exome sequencing and custom‐designed chromosomal microarray with exon coverage of primary immunodeficiency genes detected compound heterozygous mutations (one single nucleotide variant and one intragenic copy number variant involving one exon) within the IL7R gene. Mosaicism for wild‐type allele (20–30%) was detected in pretransplant blood and buccal DNA and maternal engraftment (5–10%) demonstrated in pretransplant blood DNA. This may be responsible for the patients unusual immunological phenotype compared to classical interleukin (IL)‐7Rα deficiency. Disseminated VZV was controlled with anti‐viral and immune‐based therapy, and umbilical cord blood stem cell transplantation was successful. Retrospectively performed T cell receptor excision circle (TREC) analyses completed on neonatal Guthrie cards identified absent TREC. This case emphasizes the danger of live viral vaccination in severe combined immunodeficiency (SCID) patients and the importance of newborn screening to identify patients prior to high‐risk exposures. It also illustrates the value of aggressive pathogen identification and treatment, the influence newborn screening can have on morbidity and mortality and the significant impact of newer genomic diagnostic tools in identifying the underlying genetic aetiology for SCID patients.


The Journal of Allergy and Clinical Immunology | 2008

Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome

Carla M. Davis; Vikas S. Kancherla; Ashwini Reddy; Wenyaw Chan; Hung Wen Yeh; Lenora M. Noroski; Howard M. Rosenblatt; William T. Shearer; Javier Chinen

BACKGROUND Partial DiGeorge syndrome (pDGS) presents with thymic hypoplasia and a variable decrease in T-cell numbers. Although lymphocyte proliferation to mitogens is generally preserved, it is uncertain whether the development of specific cellular immunity in pDGS is similarly preserved. OBJECTIVE We sought to study the development of antigen-specific T-cell responses in patients with pDGS with regard to their initial CD3 T-cell counts. METHODS A retrospective review of 93 patients with pDGS followed at Texas Childrens Hospital Allergy and Immunology Clinic from 1991 to 2006 was performed. Serial lymphocyte proliferation to Candida and tetanus antigens was longitudinally analyzed. Antigen-specific lymphoproliferation was compared with initial patient CD3 T-cell counts of less than the 10th percentile (n = 63), the 10th to 50th percentile (n = 20), and greater than the 50th percentile (n = 10) of age-matched normal control values. Tetanus-specific IgG levels and the number of tetanus immunizations were also studied. RESULTS The median CD3 T-cell counts at baseline in all 3 groups were as follows: 10th percentile, 1188 cells/mm(3) (range, 168-3272 cells/mm(3)); 10th to 50th percentile, 2816 cells/mm(3) (range, 1484-4155 cells/mm(3)); greater than 50th percentile, 4246 cells/mm(3) (range, 2573-6481 cells/mm(3)). Thirty-one (46%) of 68 patients with pDGS who received at least 3 tetanus vaccines had persistent Candida and tetanus-specific cellular immunity, and 24 (35%) did not have immunity to either antigen. Most (22/24) of these patients had CD3 T-cell counts at presentation of less than the 10th percentile of normal values. Protective tetanus-specific IgG titers (>0.10 IU/mL) were detected in all patients tested from the age of 2 to 85 months (n = 72). CONCLUSION Some patients with pDGS with low CD3 T-cell counts might not have specific Candida and tetanus cellular immunity.


The Journal of Allergy and Clinical Immunology | 2015

Molecular mechanisms of functional natural killer deficiency in patients with partial DiGeorge syndrome

Peilin Zheng; Lenora M. Noroski; Imelda C. Hanson; Yuhui Chen; Michelle E. Lee; Yu Huang; Michael X. Zhu; Pinaki P. Banerjee; George Makedonas; Jordan S. Orange; William T. Shearer; Dongfang Liu

BACKGROUND DiGeorge syndrome affects more than 3.5 million persons worldwide. Partial DiGeorge syndrome (pDGS), which is characterized by a number of gene deletions in chromosome 22, including the chicken tumor virus number 10 regulator of kinase (Crk)-like (CrkL) gene, is one of the most common genetic disorders in human subjects. To date, the role of natural killer (NK) cells in patients with pDGS remains unclear. OBJECTIVE We sought to define the effect of pDGS-related Crk haploinsufficiency on NK cell activation and cytotoxic immunological synapse (IS) structure and function. METHODS Inducible CrkL-silenced NK cells were used to recapitulate the pDGS, CrkL-haploinsufficient phenotype. Findings were validated by using NK cells from patients with actual pDGS. Ultimately, deficits in the function of NK cells from patients with pDGS were restored by lentiviral transduction of CrkL. RESULTS Silencing of CrkL expression inhibits NK cell function. Specifically, pDGS haploinsufficiency of CrkL inhibits accumulation of activating receptors, polarization of cytolytic machinery and key signaling molecules, and activation of β2-integrin at the IS. Reintroduction of CrkL protein restores NK cell cytotoxicity. CONCLUSION CrkL haploinsufficiency causes functional NK deficits in patients with pDGS by disrupting both β2-integrin activation and activating receptor accumulation at the IS. Our results suggest that NK cell IS quality can directly affect immune status, providing a potential target for diagnosis and therapeutic manipulation in patients with pDGS and in other patients with functional NK cell deficiencies.


Blood | 2017

Reticular dysgenesis: international survey on clinical presentation, transplantation and outcome

Manfred Hoenig; Chantal Lagresle-Peyrou; Ulrich Pannicke; Luigi D. Notarangelo; Fulvio Porta; Andrew R. Gennery; Mary Slatter; Morton J. Cowan; Polina Stepensky; Hamoud Al-Mousa; Daifulah Al-Zahrani; Sung-Yun Pai; Waleed Al-Herz; Hubert B. Gaspar; Paul Veys; Koichi Oshima; Kohsuke Imai; Hiromasa Yabe; Lenora M. Noroski; Nico Wulffraat; Karl-Walter Sykora; Pere Soler-Palacín; Hideki Muramatsu; Mariam Al Hilali; Despina Moshous; Klaus-Michael Debatin; Catharina Schuetz; Eva-Maria Jacobsen; Ansgar Schulz; Klaus Schwarz

Reticular dysgenesis (RD) is a rare congenital disorder defined clinically by the combination of severe combined immunodeficiency (SCID), agranulocytosis, and sensorineural deafness. Mutations in the gene encoding adenylate kinase 2 were identified to cause the disorder. Hematopoietic stem cell transplantation (HSCT) is the only option to cure this otherwise fatal disease. Retrospective data on clinical presentation, genetics, and outcome of HSCT were collected from centers in Europe, Asia, and North America for a total of 32 patients born between 1982 and 2011. Age at presentation was <4 weeks in 30 of 32 patients (94%). Grafts originated from mismatched family donors in 17 patients (55%), from matched family donors in 6 patients (19%), and from unrelated marrow or umbilical cord blood donors in 8 patients (26%). Thirteen patients received secondary or tertiary transplants. After transplantation, 21 of 31 patients were reported alive at a mean follow-up of 7.9 years (range: 0.6-23.6 years). All patients who died beyond 6 months after HSCT had persistent or recurrent agranulocytosis due to failure of donor myeloid engraftment. In the absence of conditioning, HSCT was ineffective to overcome agranulocytosis, and inclusion of myeloablative components in the conditioning regimens was required to achieve stable lymphomyeloid engraftment. In comparison with other SCID entities, considerable differences were noted regarding age at presentation, onset, and type of infectious complications, as well as the requirement of conditioning prior to HSCT. Although long-term survival is possible in the presence of mixed chimerism, high-level donor myeloid engraftment should be targeted to avoid posttransplant neutropenia.


The Journal of Allergy and Clinical Immunology | 2018

Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype

Irit Tirosh; Yasuhiro Yamazaki; Francesco Frugoni; Francesca Ververs; Eric J. Allenspach; Yu Zhang; Siobhan O. Burns; Waleed Al-Herz; Lenora M. Noroski; Jolan E. Walter; Andrew R. Gennery; Mirjam van der Burg; Luigi D. Notarangelo; Yu Nee Lee

Background: Mutations in recombination‐activating gene (RAG) 1 and RAG2 are associated with a broad range of clinical and immunologic phenotypes in human subjects. Objective: Using a flow cytometry–based assay, we aimed to measure the recombinase activity of naturally occurring RAG2 mutant proteins and to correlate our results with the severity of the clinical and immunologic phenotype. Methods: Abelson virus–transformed Rag2−/− pro‐B cells engineered to contain an inverted green fluorescent protein (GFP) cassette flanked by recombination signal sequences were transduced with retroviruses encoding either wild‐type or 41 naturally occurring RAG2 variants. Bicistronic vectors were used to introduce compound heterozygous RAG2 variants. The percentage of GFP‐expressing cells was evaluated by using flow cytometry, and high‐throughput sequencing was used to analyze rearrangements at the endogenous immunoglobulin heavy chain (Igh) locus. Results: The RAG2 variants showed a wide range of recombination activity. Mutations associated with severe combined immunodeficiency and Omenn syndrome had significantly lower activity than those detected in patients with less severe clinical presentations. Four variants (P253R, F386L, N474S, and M502V) previously thought to be pathogenic were found to have wild‐type levels of activity. Use of bicistronic vectors permitted us to assess more carefully the effect of compound heterozygous mutations, with good correlation between GFP expression and the number and diversity of Igh rearrangements. Conclusions: Our data support genotype‐phenotype correlation in the setting of RAG2 deficiency. The assay described can be used to define the possible disease‐causing role of novel RAG2 variants and might help predict the severity of the clinical phenotype. Graphical abstract Figure. No caption available.


The Journal of Allergy and Clinical Immunology | 2009

Role of IL-7 in the regulation of T-cell homeostasis in partial DiGeorge syndrome

Usa Tantibhaedhyangkul; Carla M. Davis; Lenora M. Noroski; Imelda C. Hanson; William T. Shearer; Javier Chinen

tum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121:685-91. 4. Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007;120: 238-46. 5. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007; 204:253-8. 6. Zhang K, Shan L, Rahman MS, Unruh H, Halayko AJ, Gounni AS. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L375-82. 7. Sukkar MB, Xie S, Khorasani NM, Kon OM, Stanbridge R, Issa R, et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 2006;118:641-8. 8. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 2006;1088:78-99. 9. Woodman L, Siddiqui S, Cruse G, Sutcliffe A, Saunders R, Kaur D, et al. Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta1. J Immunol 2008;181:5001-7.

Collaboration


Dive into the Lenora M. Noroski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carla M. Davis

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Imelda C. Hanson

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Filiz O. Seeborg

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Javier Chinen

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jordan S. Orange

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Mary E. Paul

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lisa R. Forbes

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge